name: Chronic Inflammatory Demyelinating Polyneuropathy
creation_date: '2025-12-19T01:12:52Z'
updated_date: '2026-01-26T15:28:38Z'
category: Autoimmune
parents:
- Autoimmune Disease
- Peripheral Neuropathy
disease_term:
  preferred_term: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
  term:
    id: MONDO:0006702
    label: chronic inflammatory demyelinating polyradiculoneuropathy
description: >-
  A chronic acquired immune-mediated neuropathy characterized by progressive
  or relapsing-remitting symmetric proximal and distal weakness with sensory
  involvement. Distinguished from GBS by duration greater than 8 weeks and
  chronic course.
pathophysiology:
- name: T Cell-Mediated Demyelination
  description: >-
    CD4+ and CD8+ T cells infiltrate peripheral nerves and contribute to
    demyelination. T cells recognize myelin antigens and produce inflammatory
    cytokines that damage Schwann cells.
  cell_types:
  - preferred_term: CD4+ T Cell
    term:
      id: CL:0000624
      label: CD4-positive, alpha-beta T cell
  - preferred_term: CD8+ T Cell
    term:
      id: CL:0000625
      label: CD8-positive, alpha-beta T cell
  biological_processes:
  - preferred_term: Adaptive Immune Response
    term:
      id: GO:0002250
      label: adaptive immune response
  evidence:
  - reference: PMID:37356965
    supports: SUPPORT
    snippet: >-
      Autoimmune neuropathies are a heterogeneous group of rare and disabling diseases
      in which the immune system is thought to target antigens in the peripheral
      nervous system: they usually respond to immune therapies.
    explanation: >-
      This pathology review confirms that CIDP involves immune-mediated targeting
      of peripheral nerve antigens, supporting the role of adaptive immunity including
      T cell responses in disease pathogenesis.
- name: Antibody and Complement-Mediated Damage
  description: >-
    Autoantibodies against myelin proteins and nodal/paranodal antigens
    (neurofascin, contactin-1) contribute to demyelination. Complement
    deposition amplifies nerve damage.
  biological_processes:
  - preferred_term: Complement Activation
    term:
      id: GO:0006956
      label: complement activation
  - preferred_term: Immunoglobulin Production
    term:
      id: GO:0002377
      label: immunoglobulin production
  evidence:
  - reference: PMID:35378684
    supports: SUPPORT
    snippet: >-
      The complement system appears to play a role in promoting macrophage-mediated
      demyelination.
    explanation: >-
      This review establishes the role of complement activation in CIDP pathogenesis,
      linking complement to the amplification of macrophage-mediated nerve damage.
  - reference: PMID:36346134
    supports: SUPPORT
    snippet: >-
      Besides IgG4, subclass IgG3 was detected and associated with complement binding
      and cytotoxic effects in vitro.
    explanation: >-
      Experimental evidence showing that IgG3 subclass antibodies activate complement,
      demonstrating complement-mediated pathogenic mechanisms in autoantibody-positive CIDP.
- name: Macrophage-Mediated Myelin Stripping
  description: >-
    Activated macrophages invade nerve fibers and actively strip myelin from
    axons, causing segmental demyelination visible on nerve biopsy.
  cell_types:
  - preferred_term: Macrophage
    term:
      id: CL:0000235
      label: macrophage
  biological_processes:
  - preferred_term: Inflammatory Response
    term:
      id: GO:0006954
      label: inflammatory response
  evidence:
  - reference: PMID:37356965
    supports: SUPPORT
    snippet: >-
      In contrast, the mechanisms of demyelination of other dysimmune neuropathies
      induced by macrophages are unexplained, as no antibodies have been identified
      in such cases.
    explanation: >-
      This pathology review acknowledges macrophage-induced demyelination as a distinct
      mechanism in CIDP, occurring even in cases without identified autoantibodies,
      supporting the role of innate immune responses independent of antibody-mediated damage.
  - reference: PMID:36645654
    supports: SUPPORT
    snippet: >-
      The proposed mechanisms of action of IVIg that can mediate its therapeutic effects
      are reviewed. These include anti-idiotypic interactions, inhibition of neonatal Fc
      receptors (FcRn), anti-complement activity, upregulation of inhibitory FcÎ³RIIB
      receptors, and downregulation of macrophage activation.
    explanation: >-
      IVIg therapy works in part by downregulating macrophage activation, providing indirect
      evidence that macrophages play a central pathogenic role in CIDP that can be therapeutically
      targeted.
phenotypes:
- name: Progressive Weakness
  category: Neurological
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Limb Muscle Weakness
    term:
      id: HP:0003690
      label: Limb muscle weakness
  notes: Symmetric, proximal and distal
- name: Areflexia
  category: Neurological
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Areflexia
    term:
      id: HP:0001284
      label: Areflexia
- name: Sensory Loss
  category: Neurological
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Peripheral Sensory Neuropathy
    term:
      id: HP:0000763
      label: Sensory neuropathy
  evidence:
  - reference: PMID:38330421
    supports: SUPPORT
    snippet: >-
      Sensory CIDP was diagnosed when two inclusion criteria are met: 1) acquired,
      chronic progressive or relapsing symmetrical or asymmetrical sensory polyneuropathy
      that had progressed for >2 months.
    explanation: >-
      This clinical study establishes sensory polyneuropathy as a diagnostic criterion
      and key phenotype of sensory CIDP variant, demonstrating that sensory loss is a
      prominent and treatable feature in CIDP.
- name: Fatigue
  category: Systemic
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
biochemical:
- name: CSF Protein
  presence: Elevated
  context: Without pleocytosis
- name: Anti-Neurofascin Antibodies
  presence: Variable
  context: Associated with specific CIDP subtype
- name: Anti-Contactin-1 Antibodies
  presence: Variable
  context: Associated with specific CIDP subtype
treatments:
- name: IVIG
  description: First-line therapy for most patients.
- name: Corticosteroids
  description: Alternative first-line therapy.
- name: Plasmapheresis
  description: For refractory cases or acute exacerbations.
- name: Rituximab
  description: For antibody-positive refractory cases.
classifications:
  harrisons_chapter:
  - classification_value: nervous system disorder
  - classification_value: neuromuscular disease
  - classification_value: autoimmune disease
